CLN-619

A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
30 patients (estimated)
Sponsors
Cullinan Therapeutics Inc.
Tags
Monoclonal Antibody, MICA, MICB
Trial Type
Treatment
Last Update
4 months ago
SparkCures ID
1931
NCT Identifier
NCT06381141

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.